Evidence map›Paper›PMID 38062777›Full record

ArticleThyroid : official journal of the American Thyroid Association2024

Pamela Brock, Myriam Sevigny, Sandya Liyanarachchi, Daniel F Comiskey, Wei Li, Saila Saarinen, Ayse Selen Yilmaz, Anni I Nieminen, Matthew D Ringel, Päivi Peltomäki and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid : official journal of the American Thyroid Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Pamela BrockDivision of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Myriam SevignyTranslational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1732-0583
Sandya LiyanarachchiDivision of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Diabetes, and Metabolism, Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA.
Daniel F ComiskeyDivision of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Diabetes, and Metabolism, Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA.
Wei LiDivision of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Diabetes, and Metabolism, Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA.
Saila SaarinenDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
Ayse Selen YilmazDepartment of Biomedical Informatics, The Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA.
Anni I NieminenFIMM Metabolomics Unit, Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-8999-6040
Matthew D RingelDivision of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Diabetes, and Metabolism, Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA.
Päivi PeltomäkiDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
Saara OllilaTranslational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.
Taina T NieminenDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIThe Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPOREP50CA168505 · NCI · OHIO STATE UNIVERSITY · PI DE LA CHAPELLE, ALBERT · 2013 to 2017
$10.9M
RCAN 1.4 metastasis suppressor in thyroid cancerR01CA240302 · NCI · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2020 to 2024
$2.2M
NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA168505NCI NIH HHS R01 CA240302
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic Predisposition to DiseaseThyroid Cancer, PapillaryThyroid NeoplasmsAdultFemaleHumansMaleMiddle AgedMitochondrial ProteinsPedigreePyruvate Dehydrogenase (Lipoamide)-PhosphataseMitochondrial ProteinsPDPR protein, humanPyruvate Dehydrogenase (Lipoamide)-PhosphatasehereditaryPDPRpredisposing genePTC

Identifiers

PMID38062777
PMCPMC11238834
OpenAlexW4389486211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.